SPIA
CRMD icon

Steward Partners Investment Advisory’s CorMedix CRMD Stock Holding History

Steward Partners Investment Advisory’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56M Buy
229,465
+24,980
+12% +$185K 0.01% 957
2025
Q4 		$2.38M Buy
204,485
+14,605
+8% +$161K 0.01% 727
2025
Q3 		$2.21M Buy
189,880
+24,318
+15% +$294K 0.01% 742
2025
Q2 		$2.04M Buy
165,562
+5,925
+4% +$65.4K 0.02% 714
2025
Q1 		$983K Buy
159,637
+9,803
+7% +$101K 0.01% 932
2024
Q4 		$1.21M Buy
149,834
+3,221
+2% +$32.2K 0.01% 808
2024
Q3 		$1.18M Buy
146,613
+3,910
+3% +$21.2K 0.01% 800
2024
Q2 		$618K Sell
142,703
-15,210
-10% -$77.3K 0.01% 970
2024
Q1 		$670K Buy
157,913
+19,905
+14% +$69K 0.01% 940
2023
Q4 		$519K Buy
138,008
+4,195
+3% +$14.4K 0.01% 988
2023
Q3 		$495K Buy
133,813
+2,100
+2% +$8.35K 0.01% 923
2023
Q2 		$522K Buy
131,713
+9,151
+7% +$45.3K 0.01% 921
2023
Q1 		$507K Sell
122,562
-15,500
-11% -$63.4K 0.01% 921
2022
Q4 		$583K Sell
138,062
-4,000
-3% -$14.2K 0.01% 846
2022
Q3 		$402K Sell
142,062
-6,530
-4% -$27.2K 0.01% 927
2022
Q2 		$597K Buy
148,592
+2,912
+2% +$10.8K 0.01% 799
2022
Q1 		$798K Sell
145,680
-1,200
-0.8% -$5.5K 0.01% 756
2021
Q4 		$668K Sell
146,880
-21,185
-13% -$105K 0.01% 846
2021
Q3 		$782K Buy
168,065
+20,900
+14% +$122K 0.01% 743
2021
Q2 		$1.01M Buy
147,165
+8,635
+6% +$68.7K 0.02% 663
2021
Q1 		$1.38M Buy
138,530
+63,321
+84% +$667K 0.02% 534
2020
Q4 		$559K Sell
75,209
-1,001
-1% -$6.8K 0.01% 728
2020
Q3 		$460K Sell
76,210
-3,800
-5% -$19.1K 0.01% 697
2020
Q2 		$504K Buy
80,010
+5,324
+7% +$24.6K 0.01% 625
2020
Q1 		$268K Buy
74,686
+5,926
+9% +$33.5K 0.01% 706
2019
Q4 		$500K Buy
68,760
+9,604
+16% +$58.7K 0.01% 626
2019
Q3 		$377K Sell
59,156
-5,622
-9% -$47.2K 0.01% 664
2019
Q2 		$581K Buy
64,778
+26,500
+69% +$208K 0.02% 517
2019
Q1 		$361K Buy
38,278
+22,500
+143% +$203K 0.02% 592
2018
Q4 		$101K Buy
15,778
+1,600
+11% +$10.7K ﹤0.01% 747
2018
Q3 		$69K Buy
14,178
+3,960
+39% +$9.74K ﹤0.01% 1066
2018
Q2 		$12K Buy
10,218
+500
+5% +$579 ﹤0.01% 1664
2018
Q1 		$8K Hold
9,718
– – ﹤0.01% 1638
2017
Q4 		$24K Hold
9,718
– – ﹤0.01% 1053
2017
Q3 		$25K Buy
9,718
+1,600
+20% +$3.31K ﹤0.01% 877
2017
Q2 		$17K Buy
8,118
+1,800
+28% +$6.16K ﹤0.01% 907
2017
Q1 		$51K Buy
+6,318
New +$60.3K 0.01% 544

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Steward Partners Investment Advisory's CRMD Position: Q1 2026 in Review

Steward Partners Investment Advisory increased its CorMedix (CRMD) stake by 12% in Q1 2026, buying an estimated $185K and bringing the position to 229,465 shares worth $1.56M. The position accounts for 0.01% of the portfolio, ranked #957.

Steward Partners Investment Advisory first reported a position in CRMD in Q1 2017 and has held it in 37 quarters since. The position peaked at $2.38M in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Steward Partners Investment Advisory held 229,465 shares of CorMedix worth $1.56M as of Q1 2026.
  • Steward Partners Investment Advisory bought 24,980 CorMedix shares in Q1 2026, an estimated $185K.
  • CorMedix made up 0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #957 holding.
  • Steward Partners Investment Advisory first reported a position in CorMedix in Q1 2017 and has held it in 37 quarters since.
  • Steward Partners Investment Advisory's CorMedix position peaked at $2.38M in Q4 2025.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.